Skip to main content

Immune Response BioPharma, Inc.

Home
Drug Discovery
Press Releases
Investor Relations
Royalties
Stock Information
Executive Team
Scientific Board
Clinical Trials
REMUNE Vaccine
REMUNE Rx Co-pay Card
REMUNE FULL PRESCRIBING
REMUNEX Vaccine
Remune Pediatric
RemuneVax Vaccine
NeuroVax Vaccine
NeurOral
RAVAX Vaccine
RAVAX II Vaccine
Zorcell Vaccine
DermaVax
Immunereszumab
Sepsicillin
Rare Diseases
Alliances
Vaccines Direct
Partnering
Bio Defense
Immune Response Hospital
Orchestra Therapeutics
Research Donations
About Us
Corporate Filings
Corporate ByLaws
Transfer Agent
Employment
Events
Webcast
Contact Us
Email Alerts
Member Login
Site Map
 Immune Response BioPharma, Inc. TM      Copyright © 2010-2018

Press Releases:
undefined
 
undefined

Immune Response BioPharma, Inc.  Commences $25B Class Action on Behalf of Remune HIV Patients
April 13th 2017 Class Action Lawsuit info website under construction 

Immune Response BioPharma, Inc. Files New BLA for FDA Orphan Designated Pediatric HIV Indication: 
IRBP's 2nd Remune HIV Vaccine Product Filed for FDA BLA Approval
March 31st 2017      PR.com      More:

December 27th 2016     PR.com    More: PR PDF

Immune Response BioPharma, Inc. Announces a Lottery System will be Utilized for Remune to Ensure Fairness for Initial Commercial Batches or Compassionate Use Under New IND Filing Once Vaccine is Made Available  
December 27th 2016

Immune Response BioPharma, Inc, Highlights FDA SPMS Fast Track & FDA Orphan Pediatric T Cell MS Vaccine NeuroVax First in Class & Best in Class Last Standing Treatment for SPMS in Development 
December 12th 2016

Immune Response BioPharma, Inc. Announces HIV Experts & Thought Leaders Conclusion: Remune "Highly Immunogenic"
November 19th 2016

Immune Response BioPharma, Inc. Issues Cease & Desist Letters to IP Infringers'; Warns Pharmaceutical Industry Against Patent Infringement & Consequences, IRBP will Vigorously Defend & Block any Use of it's IP of the Patented NeuroVax Technology & MS T cell Vaccination Platform
September 18th 2016

Immune Response BioPharma, Inc. Files Amended BLA for Remune with the FDA
August 6th 2016   

Immune Response BioPharma, Inc.  Reserves Stock Symbol IRBP on NASDAQ
February 13th 2016   More:    



 


Immune Response BioPharma, Inc.TM 
Copyright (C) 2010-2018  All Rights Reserved     www.immuneresponse.net